Last $14.21 USD
Change Today +0.12 / 0.85%
Volume 1.0K
DSKYF On Other Exchanges
Symbol
Exchange
Tokyo
OTC US
OTC US
Frankfurt
As of 8:10 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

daiichi sankyo co ltd (DSKYF) Snapshot

Open
$14.21
Previous Close
$14.09
Day High
$14.21
Day Low
$14.21
52 Week High
01/14/14 - $18.77
52 Week Low
12/16/14 - $14.01
Market Cap
10.1B
Average Volume 10 Days
367.1
EPS TTM
--
Shares Outstanding
709.0M
EX-Date
03/27/15
P/E TM
--
Dividend
$63.03
Dividend Yield
4.00%
Current Stock Chart for DAIICHI SANKYO CO LTD (DSKYF)

Related News

No related news articles were found.

daiichi sankyo co ltd (DSKYF) Related Businessweek News

No Related Businessweek News Found

daiichi sankyo co ltd (DSKYF) Details

Daiichi Sankyo Company, Limited engages in the research, development, manufacture, import, sale, and marketing of pharmaceutical products in Japan and internationally. The company’s product portfolio includes generic pharmaceuticals, vaccines, and over-the-counter (OTC) medicines. Its principal products include Olmesartan, an anti-hypertensive agent; Prasugrel, an antiplatelet agent; Edoxaban, an anticoagulant; Memary and Donepezil for the treatment of alzheimer’s disease; Nexium for treating reflux esophagitis; Pralia for osteoporosis; Tenelia for treatment for type 2 diabetes mellitus; and ActHIB, a haemophilus b conjugate vaccine, as well as Denosumab to treat and prevent various bone disorders, including osteoporosis and bone metastases. The company’s products OTC comprise Loxonin S, an analgesic and anti-inflammatory drug; Transino II, a drug for the improvement of spots; and Traful Ointment for stomatitis treatment. It also markets therapies in hypertension, dyslipidemia, and bacterial infections, as well as treatments for thrombotic disorders. In addition, the company researches and develops therapies in oncology and cardiovascular-metabolic diseases, including biologics. Further, it manufactures and sells cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates, as well as pharmaceuticals and drugs for animals. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Tokyo, Japan.

32,791 Employees
Last Reported Date: 06/23/14
Founded in 1899

daiichi sankyo co ltd (DSKYF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

daiichi sankyo co ltd (DSKYF) Key Developments

Daiichi Sankyo Company, Limited Launches New Formulation of Lixiana(R) 60 Mg Tablets (Edoxaban) in Japan

Daiichi Sankyo Company, Limited announced that it has launched a new formulation of LIXIANA(R) 60 mg Tablets (JAN: Edoxaban Tosilate Hydrate, INN: edoxaban, approval to market: September 26, 2014; NHI drug price listing: November 25, 2014) in Japan for the recently approved indications: the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and the treatment and recurrence prevention of venous thromboembolism (VTE) [deep vein thrombosis (DVT) and pulmonary thromboembolism (PE)]. LIXIANA was approved in Japan in April 2011 for the prevention of VTE after major orthopedic surgery and was launched in July 2011. LIXIANA was also approved in Japan in September 2014 for the prevention of ischemic stroke and systemic embolism in patients with NVAF and for the treatment and recurrence prevention of VTE. Daiichi Sankyo has also filed for approval of once-daily edoxaban in both the U.S. and EU for the reduction in risk of stroke in NVAF and for treatment of symptomatic VTE in patients with DVT and/or PE.

Daiichi Sankyo and UCB Partner to Commercialize Epilepsy Drug in Japan

Daiichi Sankyo Company, Limited and UCB Biopharma SPRL have entered into an agreement to jointly commercialize Lacosamide for epilepsy patients in Japan. Under this agreement, UCB will manufacture and supply the product for commercialization. Daiichi Sankyo will manage the distribution and book sales, with both Daiichi Sankyo and UCB commercializing Lacosamide in Japan.

Daiichi Sankyo Company Announces Dividend for the Second Quarter Ended Sep. 30, 2014, Payable on December 1, 2014; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2015

Daiichi Sankyo Company, Limited announced an interim dividend of ¥30 per share for the second quarter ended Sep. 30, 2014. The Dividend is payable on December 1, 2014. The company provided interim dividend guidance for the fiscal year ending March 31, 2015. The company expects, to pay a year end dividend of JPY 30.00 per share compared to a dividend of JPY 30.00 per share announced for same period of previous year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DSKYF:US $14.21 USD +0.12

DSKYF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Array BioPharma Inc $4.75 USD +0.11
BioCryst Pharmaceuticals Inc $12.01 USD +0.175
BioMerieux €86.13 EUR -0.07
Infinity Pharmaceuticals Inc $16.70 USD +0.05
Ipsen SA €43.00 EUR +0.18
View Industry Companies
 

Industry Analysis

DSKYF

Industry Average

Valuation DSKYF Industry Range
Price/Earnings 14.0x
Price/Sales 1.0x
Price/Book 1.1x
Price/Cash Flow 14.1x
TEV/Sales 0.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DAIICHI SANKYO CO LTD, please visit www.daiichisankyo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.